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Effect of simvastatin on the lipid profile of hemodialysis patients. hibit dyslipidemia, which is thought to be one of the
Background. Simvastatin, a 3-hydroxy 3-methylglutaryl co- main causes of atherosclerosis in these patients [3, 4].
enzyme A (HMG-CoA) reductase inhibitor, is used widely The major symptoms of dyslipidemia in HD patients arefor treatment of hypercholesterolemia. Simvastatin may be
mild hypertriglyceridemia and a decreased concentrationa suitable treatment for dyslipidemia in hemodialysis (HD)
of high-density lipoprotein cholesterol (HDL-C) [5, 6],patients. However, investigation of the side-effects and safety
of long-term administration of simvastatin to HD patients has although a few HD patients also exhibit hypercholester-
been limited. In this study, we investigated the effects and olemia. The treatment of dyslipidemia in HD patients
safety of simvastatin and its effects on lipoprotein metabolism may prevent the development of atherosclerosis.in hypercholesterolemic patients on HD.
Simvastatin, an HMG-CoA reductase inhibitor, is ex-Methods. Simvastatin was administered at a dosage of 5
creted by the kidney at lower concentrations than prava-mg/day for 24 weeks to 38 HD patients with high serum total
cholesterol (TC) levels (200 mg/dl) or low high-density lipopro- statin, an alternative HMG-CoA reductase inhibitor [7].
tein cholesterol (HDL-C) levels (35 mg/dl). Every four weeks, However, investigation of the side-effects and safety of
serum lipids, apolipoprotein, lipoprotein(a) [Lp(a)] and malon-
long-term administration of simvastatin to HD patientsdialdehyde (MDA) levels were measured. In addition, lipid
has been limited. In this study, we investigated the effectslevels were determined in each lipoprotein fraction separated
by ultracentrifugation. and safety of simvastatin and its effects on lipoprotein
Results. After 24 weeks of simvastatin administration, TC metabolism in hypercholesterolemic patients on HD.
significantly decreased by 25.7%, and low-density lipoprotein
cholesterol (LDL-C) was significantly decreased by 33.6%. Tri-
glyceride (TG) and HDL-C showed no significant changes. METHODS
Apolipoprotein (apo) B significantly decreased by 24.5% and
Between August 1992 and December 1993, we exam-apo E by 30.0%. No significant changes were observed in the
other apolipoproteins. MDA was also significantly decreased, ined 38 stable HD patients (20 males and 18 females)
whereas Lp(a) was not significantly altered. In the lipoprotein with high serum total cholesterol (TC) levels (200 mg/dl)
fractions, very LDL cholesterol (VLDL-C), intermediate- or low HDL-C levels (35 mg/dl) at eight hospitals indensity lipoprotein cholesterol (IDL-C), LDL1 cholesterol
Osaka and Wakayama, Japan. The average age of pa-(LDL1-C), and LDL2 cholesterol (LDL2-C) showed significant
tients was 58.7 6 12.5 years. Patients had undergone HDdecreases. No particular side-effects were observed during the
12 months of simvastatin administration. for 4.99 6 4.16 years. Chronic renal failure in the subjects
Conclusions. These results suggest that simvastatin appears was caused by chronic glomerulonephritis (N 5 22), dia-
to be safe and effective in HD patients with hypercholesterol- betic nephropathy (N 5 11), nephrosclerosis (N 5 3),emia.
and unknown (N 5 2).
Simvastatin was administered at a dosage of 5 mg/day
for 24 weeks to these patients. Monthly blood samplesThe incidence of cardiovascular and cerebrovascular
were drawn in the morning from the arterial side of thediseases derived from atherosclerosis is very high in he-
arteriovenous fistula before HD. Routine hematologicmodialysis (HD) patients [1, 2]. HD patients often ex-
and biochemical parameters, including creatine phos-
phokinase (CPK), serum lipids, apolipoproteins, Lp(a)
and malondialdehyde (MDA) levels were measured. InKey words: chronic renal failure, hypercholesterolemia, hyperlipid-
emia, lipoprotein metabolism. addition, lipid levels were determined in each lipoprotein
fraction separated by ultracentrifugation. Low-density 1999 by the International Society of Nephrology
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Fig. 1. Changes in serum total cholesterol,
triglyceride, low-density lipoprotein choles-
terol, and high-density lipoprotein cholesterol
before and after simvastatin administration.
*P , 0.001.
lipoprotein cholesterol (LDL-C) was calculated from
Friedwald’s formula [8].
Statistical analysis was performed by Wilcoxon matched
pairs test.
P values less than 0.05 were considered to be significant.
RESULTS
Changes in serum lipid levels are shown in Figure 1.
After both 12 weeks and 24 weeks of simvastatin admin-
istration, TC and LDL-C levels decreased significantly.
After 24 weeks, TC decreased by 25.7% (232.4 6 47.2 →
172.6 6 32.9 mg/dl) and LDL-C by 33.6% (151.0 6
36.9 → 100.3 6 29.3 mg/dl). Triglyceride (TG) decreased
but not significantly. HDL-C showed no significant
changes (Fig. 1). The apolipoproteins apo B and apo E
decreased significantly after both 12 weeks and 24 weeks
compared with levels before simvastatin administration.
After 24 weeks, apo B decreased by 24.5% (115.4 6
20.6 → 87.1 6 20.5 mg/dl) and apo E by 30.0% (6.9 6
2.8 → 4.9 6 3.0 mg/dl; Fig. 2). No significant changes
were observed in the other apolipoproteins.
Cholesterol decreased significantly after both 12 weeks
and 24 weeks in the VLDL (46.9 6 16.8 → 37.7 6 18.3
mg/dl), LDL1 (96.0 6 21.5 → 65.4 6 22.5 mg/dl) and
LDL2 (18.8 6 8.5 → 12.9 6 6.8 mg/dl) fractions. In the
intermediate-density lipoprotein (IDL) fraction, choles-
terol decreased significantly only after 12 weeks (31.0 6
37.9 → 14.8 6 5.9 mg/dl). TG decreased significantly only
in the LDL1 fraction (37.6 6 13.9 mg/d3 → 27.1 6 9.2
mg/d3). MDA significantly decreased after both 12 weeks
and 24 weeks (4.1 6 1.0 → 3.6 6 0.7 mg/dl). Lp(a) was Fig. 2. Changes in apo B and apo E before and after simvastatin admin-
istration. *P , 0.001.not significantly altered (35.0 6 24.3 → 36.1 6 23.5 mg/dl).
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After six months, CPK increased slightly compared tors [9]. However, no incidents of severe clinical symp-
toms including rhabdomyolysis were observed after 12with levels before simvastatin administration. However,
months of simvastatin administration.the levels were within the normal range of CPK. Simi-
Our results indicated that simvastatin administrationlarly, no patients showed an increase in CPK above the
appears to be safer in HD patients because renal excre-normal range after 12 months of simvastatin administra-
tion is minimal. However, to avoid side-effects, it is im-tion. After about five years of observation of several
portant to monitor the CPK levels and other biochemicalpatients, no incidents of rhabdomyolysis or other clinical
parameters of HD patients. More large-scale and long-symptoms were reported.
term studies are necessary to demonstrate that treatment
of dyslipidemia with HMG-CoA reductase inhibitors de-
DISCUSSION creases atherosclerotic complications in HD patients.
Hypercholesterolemia is considered to be an impor-
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that define the treatment effects of lipid-lowering agents
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